20.500.12556/DiRROS-12404
Naše izkušnje z zdravilom bevacizumab v primarnem zdravljenju epitelijskega raka jajčnikov
Our experience with bevacizumab in the primary treatment of epithelial ovarian cancer
Izhodišče: Zdravilo bevacizumab uporabljamo v sklopu primarnega sistemskega zdravljenja napredovalega epitelijskega raka jajčnikov v kombinaciji s paklitakselom in karboplatinom od leta 2013.
Namen: Prikazati učinkovitost in varnost zdravljenja z bevacizumabom v redni klinični praksi v sklopu primarnega zdravljenja raka jajčnikov.
Metode: V retrospektivno analizo smo vključili bolnice z epitelijskim rakom jajčnikov, ki so se zdravile z bevacizumabom na Onkološkem inštitutu Ljubljana v obdobju od 1. 1. 2013 do 31. 12. 2016. Cilja raziskave sta bila varnost in učinkovitost (preživetje brez ponovitve bolezni, celokupno preživetje) zdravljenja z bevacizumabom. Raziskavo je odobrila etična komisija na Onkološkem inštitutu Ljubljana.
Rezultati: V opazovanem obdobju je bilo z bevacizumabom zdravljenih 111 bolnic z napredovalim epitelijskim rakom jajčnikov. Najpogostejši neželeni učinki so bili: bolečine (52 %), krvavitev (45 %), arterijska hipertenzija (44 %). Resne neželene učinke (stopnja 3/4) je imelo 12 % bolnic: venska tromboza/ embolija (3 %), proteinurija (3 %), arterijska hipertenzija (2 %), krvavitev (2 %), bolečine (1 %), fistula (1 %). Mediani čas sledenja je bil 59 mesecev. Mediano preživetje brez ponovitve bolezni je bilo 18 mesecev, mediano celokupno preživetje pa 41 mesecev.
Zaključki: Zdravljenje z bevacizumabom v redni klinični praksi je varno in učinkovito ‒ v skladu z do zdaj znanimi rezultati prospektivnih raziskav GOG 218 in ICON 7.
Introduction: Bevacizumab has been used in advanced epithelial ovarian cancer patients as a part of standard primary systemic therapy together with paclitaxel and carboplatin combination chemotherapy since 2013.
Aim of study: To evaluate the safety and efficacy of bevacizumab in treatment of patients with advanced epithelial ovarian cancer in daily clinical practice.
Methods: Retrospective analysis of patients with advanced epithelial cancer treated with bevacizumab at the Institute of Oncology Ljubljana in the period from 1 Jan 2013 to 31 Dec 2016. The end points of the study were safety and efficacy (relapse-free survival, overall survival). The study was approved by our institutional ethics board.
Results: In the observed period, a total of 111 patients with advanced epithelial ovarian cancer were treated with bevacizumab. The most common adverse events were: pain (52%), bleeding (45%), and arterial hypertension (44%). Serious adverse events (grade 3/4) were observed in 12% of patients: 3% venous thrombosis/ embolism, 3% proteinuria, 2% arterial hypertension, 2% bleeding, 1% pain, and 1% fistula. Median follow up was 59 months. Median progression-free survival was 18 months, while median overall survival was 41 months.
Conclusions: Treatment with bevacizumab in daily clinical practice is safe and effective – in concordance with published data from prospective studies GOG 218 and ICON 7.
rak jajčnikov
epitelijski rak
bevacizumab
kemoterapija
true
false
true
Slovenski jezik
Angleški jezik
by Authors
Neznano
2020-09-09 11:30:38
2020-09-09 11:30:38
2022-08-18 03:37:13
0000-00-00 00:00:00
2020
0
0
str. 20-24
št. 1
Letn. 24
2020
0000-00-00
Zaloznikova
Objavljeno
NiDoloceno
0000-00-00
0000-00-00
0000-00-00
618.1
1408-1741
10.25670/oi2020-0030n
24701955
65324032
RAZ_Skof_Erik_i2020.pdf
RAZ_Skof_Erik_i2020.pdf
1
CCEB34A438FAA2ACC1D4DE36538A2489
a4cb3e88224f51ddb935b668a3186577f244b7b8796a85eec2d073f2a7d40f00
4e23540b-17b6-11ed-b6b8-001a4af901a5
https://dirros.openscience.si/Dokument.php?lang=slv&id=14961
Onkološki inštitut Ljubljana
Onkologija : strokovni časopis za zdravnike
0
0
0